SCHEMBL19924203

SCHEMBL19924203

CCCC[C@H](CNC(C)=O)NC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 3/20 0.44
CA2 P00918 3/20 0.37
MAPK1 P28482 1/20 0.37
PLA2G2A P14555 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
PAOX Q6QHF9 1/20 0.35
LCK P06239 1/20 0.35
PPARD Q03181 1/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
ZDHHC7 Q9NXF8 1/20 0.35
PLA2G10 O15496 1/20 0.35
CA1 P00915 2/20 0.34
CNR2 P34972 1/20 0.34
SIRT6 Q8N6T7 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19924205 1.00 PLA2G2C (0.44) PLA2G2CCA2MAPK1PLA2G2AMTNR1A
SCHEMBL19520146 0.81 PLA2G2C (0.42) PLA2G2CCA2MAPK1PLA2G2AMTNR1A
SCHEMBL19520115 0.81 PLA2G2C (0.42) PLA2G2CCA2MAPK1PLA2G2AMTNR1A
SCHEMBL1388452 0.79 CA2 (0.48) PLA2G2CCA2MAPK1DPP7PLA2G10
SCHEMBL14844704 0.79 CYP2D6 (0.48) MAPK1MTNR1AMTNR1B
SCHEMBL20914941 0.79 PLA2G2C (0.51) PLA2G2CCA2MAPK1DPP7PLA2G10
SCHEMBL4856257 0.79 PLA2G2C (0.56) PLA2G2CCA2MAPK1LCKPPARD
SCHEMBL18125230 0.78 CTSK (0.51)
SCHEMBL4820666 0.77 PLA2G2C (0.46) PLA2G2CCA2MAPK1PLA2G10CA1
SCHEMBL16762206 0.77 PLA2G2C (0.46) PLA2G2CCA2MAPK1PLA2G10CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827609-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2023-11-28 US disclosed
EP-3507276-B1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES INC (US) 2021-11-03 EP disclosed
US-11124487-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2021-09-21 US disclosed
EP-3507288-B1 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE DERIVATIES AS TOLL LIKE RECEPTOR MODULATORS GILEAD SCIENCES INC (US) 2020-08-26 EP disclosed
US-10640499-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2020-05-05 US disclosed
US-10370342-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-20180086755-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2018-03-29 US disclosed
US-20180065938-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370342-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885
US-10640499-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 PLA2G2C 1895/4885CA2 3412/4885MAPK1 1427/4885
US-11124487-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885
US-20180086755-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885
US-20180065938-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885
US-11827609-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 PLA2G2C 2105/4885CA2 3419/4885MAPK1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.